National Institutes of Health-sponsored workshop on inflammation and immunity in dilated cardiomyopathy

Mayo Clinic Proceedings

Volumn 81, Issue 2, 2006, Pages 199-204

  Cooper, Leslie T ^a   Virmani, Renu ^b   Chapman, Nora M ^c   Frustaci, Andrea ^d   Rodeheffer, Richard J ^a   Cunningham, Madeleine W ^e   McNamara, Dennis M ^f  

^a Mayo Clinic   (United States)

^b International Registry of Pathology   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; ENVIRONMENTAL FACTOR; HEALTH CARE ORGANIZATION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS GENOME; VIRUS MYOCARDITIS;

EID: 32144444202     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.2.199     Document Type: Conference Paper

References (68)

1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant. 2005;24:945-955.
2. Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). Am J Cardiol. 1992;69:1458-1466.
3. Lisman KA, Stetson SJ, Koerner MM, Farmer JA, Torre-Amione G. The role of inflammation in the pathogenesis of heart failure. Curr Cardiol Rep. 2002;4:200-205.
4. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation. 2001;104:1076-1082.
5. Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol. 2003;42:466-472.
6. Oberste MS, Maher K, Pallansch MA. Evidence for frequent recombination within species human enterovirus B based on complete genomic sequences of all thirty-seven serotypes. J Virol. 2004;78:855-867.
7. Kuhl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793-2798.
8. Hufnagel G, Pankuweit S, Richter A, Schonian U, Maisch B. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID): first epidemiological results. Herz. 2000;25:279-285.
9. Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model: antiviral and anti-inflammatory effects. Circulation. 1995;92:1604-1611.
10. Rotbart HA, Webster AD, Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. 2001;32:228-235.
11. Bowles NE, Javier Fuentes-Garcia F, Makar KA, Li H, et al. Analysis of the coxsackievirus B-adenovirus receptor gene in patients with myocarditis or dilated cardiomyopathy. Mol Genet Metabol. 2002;77:257-259.
12. Satoh M, Nakamura M, Akatsu T, et al. Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin Sci (Lond). 2003;104:577-584.
13. Badorff C, Lee GH, Lamphear BJ, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5:320-326.
14. Shioji K, Kishimoto C, Nakayama Y, Sasayama S. Strain difference in rats with experimental giant cell myocarditis. Jpn Circ J. 2000;64:283-286.
15. Herskowitz A, Wolfgram LJ, Rose NR, Beisel KW. Coxsackievirus B3 murine myocarditis: a pathologic spectrum of myocarditis in genetically defined inbred strains. J Am Coll Cardiol. 1987;9:1311-1319.
16. Matsumori A, Kawai C. An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. Circulation. 1982;65:1230-1235.
17. Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM. Sex-related survival differences in murine cardiomyopathy are associated with difference in TNF-receptor expression. J Clin Invest. 2000;106:589-597.
18. Huber S, Shi C, Budd RC. Gammadelta T cells promote a Th1 response during coxsackievirus B3 infection in vivo: role of Fas and Fas ligand. J Virol. 2002;76:6487-6494.
19. Anderson DR, Carthy CM, Wilson JE, Yang D, Devine DV, McManus BM. Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers. J Virol. 1997;71:8841-8845.
20. Marone G, Granata F, Forte V, Di Maro E, Arbustini E, Genovese A. Role of human heart mast calls in immunologic and inflammatory mechanisms underlying cardiovascular disorders. In: Matsumori A, ed. Cardiomyopathies and Heart Failure. Boston, Mass: Kluwer Academic Publishers; 2003:185-198.
21. Selinka HC, Wolde A, Pasch A, et al. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis. J Med Virol. 2002;67:224-233.
22. Luo H, Zhang J, Dastvan F, et al. Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J Virol. 2003;77:1-9.
23. Huber S A, Lodge PA. Coxsackievirus B-3 myocarditis: identification of different pathogenic mechanisms in DBA/2 and Balb/c mice. Am J Pathol. 1986;122:284-291.
24. Huber SA, Cunningham MW. Streptococcal M protein peptide with similarity to myosin induces CD4+ T cell-dependent myocarditis in MRL/++ mice and induces partial tolerance against coxsackieviral myocarditis. J Immunol. 1996;156:3528-3534.
25. Gauntt CJ, Tracy SM, Chapman N, et al. Coxsackievirus-induced chronic myocarditis in murine models. Eur Heart J. 1995;16(suppl O):56-58.
26. McManus BM, Chow LH, Wilson JE, et al. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol. 1993;68:159-169.
27. Neu N, Beisel KW, Traystman MD, Rose NR, Craig SW. Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis. J Immunol. 1987;138:2488-2492.
28. Wolfgram LJ, Beisel KW, Herskowitz A, Rose NR. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J Immunol. 1986;136:1846-1852.
29. Rose NR, Beisel KW, Herskowitz A, et al. Cardiac myosin and autoimmune myocarditis. Ciba Found Symp. 1987;129:3-24.
30. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol. 1991;147:2141-2147.
31. Donermeyer DL, Beisel KW, Allen PM, Smith SC. Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. J Exp Med. 1995;182:1291-1300.
32. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol. 1990;57:250-262.
33. Galvin JE, Hemric ME, Kosanke SD, Factor SM, Quinn A, Cunningham MW. Induction of myocarditis and valvulitis in lewis rats by different epitopes of cardiac myosin and its implications in rheumatic carditis. Am J Pathol. 2002;160:297-306.
34. Wegmann KW, Zhao W, Griffin AC, Hickey WF, Identification of myocarditogenic peptides derived from cardiac myosin capable of inducing experimental allergic myocarditis in the Lewis rat: the utility of a class II binding motif in selecting self-reactive peptides. J Immunol. 1994;153:892-900.
35. Li Y, Heuser JS, Kosanke SD, Hemric M, Cunningham MW. Cryptic epitope identified in rat and human cardiac myosin S2 region induces myocarditis in the Lewis rat. J Immunol. 2004;172:3225-3234.
36. Liao L, Sindhwani R, Rojkind M, Factor S, Leinwand L, Diamond B. Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med. 1995;181:1123-1131.
37. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogerietic and clinical significance. Eur J Heart Fail. 2002;4:411-417.
38. Caforio AL, Goldman JH, Haven AJ, Baig KM, McKenna WJ. Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol. 1996;54:157-163.
39. Li Y, Heuser JS, Kosanke SD, Hemric M, Cunningham MW. Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cells. Am J Pathol. 2005;167:5-15.
40. Smith SC, Allen PM. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ Res. 1992;70:856-863.
41. Rayman MP. The importance of selenium to human health. Lancet. 2000;356:233-241.
42. Tan J, Zhu W, Wang W, et al. Selenium in soil and endemic diseases in China. Sci Total Environ. 2002;284:227-235.
43. Combs GF Jr, Clark LC, Turnbull BW. Reduction of cancer risk with an oral supplement of selenium. Biomed Environ Sci. 1997;10:227-234.
44. Li Y, Peng T, Yang Y, Niu C, Archard LC, Zhang H. High prevalence of enteroviral genomic sequences in myocardium from cases of endemic cardiomyopathy (Keshan disease) in China. Heart. 2000;83:696-701.
45. Beck MA. Selenium and host defence towards viruses. Proc Nutr Soc. 1999;58:707-711.
46. Cermelli C, Vinceti M, Scaltriti E, et al. Selenite inhibition of Coxsackie virus B5 replication: implications on the etiology of Keshan disease. J Trace Elem Med Biol. 2002;6:41-46.
47. Nelson HK, Shi Q, Van Dael P, et al. Host nutritional selenium status as a driving force for influenza virus mutations. FASEB J. 2001;15:1846-1848.
48. Beck MA, Handy J, Levander OA. Host nutritional status: the neglected virulence factor. Trends Microbiol. 2004;12:417-423.
49. Centeno JA, Pestaner JP, Mullick FG, Virmani R. An analytical comparison of cobalt cardiomyopathy and idiopathic dilated cardiomyopathy. Biol Trace Elem Res. 1996;55:21-30.
50. Frustaci A, Magnavita N, Chimenti C, et al. Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. J Am Coll Cardiol. 1999;33:1578-1583.
51. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348:1647-1655.
52. Nugent AW, Daubeney PE, Chandros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348:1639-1646.
53. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1:3-14.
54. Grogan M, Redfield MM, Bailey KR, et al. Long-terra outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;26:80-84.
55. Wu LA, Lapeyre AC III, Cooper LT. Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis. Mayo Clin Proc. 2001;76:1030-1038.
56. Cooper LT Jr, Berry GJ, Shabetai R, Multicenter Giant Cell Myocarditis Study Group Invesigators. Idiopathic giant-cell myocarditis-natural history and treatment. N Engl J Med. 1997;336:1860-1866.
57. Cooper LT, Zehr KJ. Biventricular assist device placement and immunosuppression as therapy for necrotizing eosinophilic myocarditis. Nat Clin Pract Cardiovasc Med. 2005;2:544-548.
58. Murphy JG, Wright RS, Bruce GK, et al. Eosinophilic-lymphocytic myocarditis after smallpox vacciniation. Lancet. 2003;362:1378-1380.
59. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109:1250-1258.
60. Magnusson C, Vaux DL. Signalling by CD95 and TNF receptors: not only life and death. Immunol Cell Biol. 1999;77:41-46.
61. Fuse K, Kodama M, Okura Y, et al. Predictors of disease course in patients with acute myocarditis. Circulation. 2000;102:2829-2835.
62. Mason JW, O'Connell JB, Herskowitz A, et al. Myocarditis Treatment Trial Investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269-275.
63. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254-2259.
64. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107:857-863.
65. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39-45.
66. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220-225.
67. Staudt A, Bohm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation. 2002;106:2448-2453.
68. Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol. 2002;39:646-652.